Zu den Inhalten springen

Institut für Klinische Pathologie

Arbeitsgruppe PD Dr. med. Peter Bronsert

Forschungsschwerpunkte der Arbeitsgruppe liegen im Bereich maligner epithelialer Tumoren des Gastrointestinaltraktes (Schwerpunkt pankreatobiliäres System) und der weiblichen Geschlechtsorgane (Schwerpunkt Mamma).

Neben den klinischen Partner der Uniklinik Freiburg kooperiert die Arbeitsgruppe mit Instituten der Albert-Ludwigs-Universität Freiburg und der Klinik für Allgemeine Chirurgie des Universitätsklinikums Schleswig Holstein, Campus Lübeck.
Herr PD Dr. med. Peter Bronsert ist assoziierter Forscher beim Deutschen Konsortium für Translationale Krebsforschung und koordiniert die CCCF-Biobank.

  • Mechanismen der Epithelial-Mesenchymalen-Transition
  • Tumor-Stroma-Interaktionen
  • Dreidimensionale Rekonstruktionen solider Tumoren
  • miRNA Expressionsmuster solider Tumoren
  • Dreidimensionale Rekonstruktion solider Tumoren
  • MALDI Imaging
Moritz Bader Arzt, Doktorand
Peter BronsertPD Dr. med.
Kathrin Enderle-AmmourDr. med.
Hannah FüllgrafÄrztin
Markus Hoernercand. med., Doktorand
Selina KieferDr. med.
Franziska Lindnercand. med., Doktorandin
Anne-Marie LüchtenborgDr. rer. nat.
Madlen Marquardtcand. med., Doktorandin
Sylvia Timme-BronsertDr. med.
Astrid Vahingercand. med., Doktorandin
Kristin WernerDr. med.

PD Dr. Peter Bronsert
Institute of Pathology
University Hospital Freiburg
Breisacher Strasse 115a
D-79106 Freiburg
Germany

Tel:  +49 761 270 81290
Fax: +49 761 270 81930  
peter.bronsert@uniklinik-freiburg.de

Erst und Letztautorenschaften (* geteilte Autorenschaft) 2018

2018

1. Loss of PSMA Expression in Non-neuroendocrine Dedifferentiated Acinar Prostate Cancer. Bronsert P, Reichel K, Ruf J. Clin Nucl Med. 2018 Jul;43(7):526-528. doi: 10.1097/RLU.0000000000002100.

2. Morphology of Immunomodulation in Breast Cancer Tumor Draining Lymph Nodes Depends on Stage and Intrinsic Subtype. Seidl M, Bader M, Vaihinger A, Wellner UF, Todorova R, Herde B, Schrenk K, Maurer J, Schilling O, Erbes T, Fisch P, Pfeiffer J, Hoffmann L, Franke K, Werner M, Bronsert P. Sci Rep. 2018 Mar 28;8(1):5321. doi: 10.1038/s41598-018-23629-3.

 

2017

3. The Role of Fibroblasts in Pancreatic Cancer: Extracellular Matrix Versus Paracrine Factors. Bolm L, Cigolla S, Wittel UA, Hopt UT, Keck T, Rades D, Bronsert P*, Wellner UF. Transl Oncol. 2017 Jun 25;10(4):578-588. doi: 10.1016/j.tranon.2017.04.009.

4. Form follows function: Morphological and immunohistological insights into epithelial-mesenchymal transition characteristics of tumor buds. Enderle-Ammour K, Bader M, Ahrens TD, Franke K, Timme S, Csanadi A, Hoeppner J, Kulemann B, Maurer J, Reiss P, Schilling O, Keck T, Brabletz T, Stickeler E, Werner M, Wellner UF, Bronsert P. Tumour Biol. 2017 May;39(5):1010428317705501. doi:10.1177/1010428317705501.

5. The Prognostic Impact of the Carcinoembryonic Antigen in Ampullary Cancer - A Retrospective Single Center Study. Fuellgraf H, Schilling O, Lai ZW, Kulemann B, Timme S, Makowiec F, Shahinian JH, Hoeppner J, Werner M, Hopt UT, Wellner UF, Bronsert P*. J Cancer. 2017 Feb 25;8(4):657-664. doi: 10.7150/jca.16200. eCollection 2017.

 

2016

6. Histopathological tumor invasion of the mesenterico-portal vein is characterized by aggressive biology and stromal fibroblast activation. Lapshyn H, Bolm L, Kohler I, Werner M, Billmann FG, Bausch D, Hopt UT, Makowiec F, Wittel UA, Keck T, Bronsert P*, Wellner UF. HPB (Oxford). 2017 Jan;19(1):67-74. doi: 10.1016/j.hpb.2016.10.002. Epub 2016 Nov 5.

7. Characterization of various cell lines from different ampullary cancer subtypes and cancer associated fibroblast-mediated responses. Lai ZW, Bolm L, Fuellgraf H, Biniossek ML, Makowiec F, Hopt UT, Werner M, Keck T, Bausch D, Sorio C, Scarpa A, Schilling O, Bronsert P, Wellner UF. BMC Cancer. 2016 Mar 8;16(1):195. doi: 10.1186/s12885-016-2193-5.

8. Mesopancreatic Stromal Clearance Defines Curative Resection of Pancreatic Head Cancer and Can Be Predicted Preoperatively by Radiologic Parameters: A Retrospective Study. Wellner UF, Krauss T, Csanadi A, Lapshyn H, Bolm L, Timme S, Kulemann B, Hoeppner J, Kuesters S, Seifert G, Bausch D, Schilling O, Vashist YK, Bruckner T, Langer M, Makowiec F, Hopt UT, Werner M, Keck T, Bronsert P. Medicine (Baltimore). 2016 Jan;95(3):e2529. doi: 10.1097/MD.0000000000002529.

9. Prognostic factors after pancreatoduodenectomy with en bloc portal venous resection for pancreatic cancer. Lapshyn H, Bronsert P, Bolm L, Werner M, Hopt UT, Makowiec F, Wittel UA, Keck T, Wellner UF, Bausch D. Langenbecks Arch Surg. 2016 Feb;401(1):63-9. doi: 10.1007/s00423-015-1363-2. Epub 2016 Jan 6.

 

2014

10. Cancer cell invasion and EMT marker expression: a three-dimensional study of the human cancer-host interface. Bronsert P, Enderle-Ammour K, Bader M, Timme S, Kuehs M, Csanadi A, Kayser G, Kohler I, Bausch D, Hoeppner J, Hopt UT, Keck T, Stickeler E, Passlick B, Schilling O, Reiss CP, Vashist Y, Brabletz T, Berger J, Lotz J, Olesch J, Werner M, Wellner UF. J Pathol. 2014 Nov;234(3):410-22. doi: 10.1002/path.4416

11. Prognostic significance of Zinc finger E-box binding homeobox 1 (ZEB1) expression in cancer cells and cancer-associated fibroblasts in pancreatic head cancer. Bronsert P, Kohler I, Timme S, Kiefer S, Werner M, Schilling O, Vashist Y, Makowiec F, Brabletz T, Hopt UT, Bausch D, Kulemann B, Keck T, Wellner UF. Surgery. 2014 Jul;156(1):97-108. doi: 10.1016/j.surg.2014.02.018.

12. Impact of routinely employed procedures for tissue processing on the proteomic analysis of formalin-fixed paraffin-embedded tissue. Bronsert P, Weißer J, Biniossek ML, Kuehs M, Mayer B, Drendel V, Timme S, Shahinian H, Küsters S, Wellner UF, Lassmann S, Werner M, Schilling O. Proteomics Clin Appl. 2014 Oct;8(9-10):796-804. doi: 10.1002/prca.201300082.

 

2013

13. Intestinal-type of differentiation predicts favourable overall survival: confirmatory clinicopathological analysis of 198 periampullary adenocarcinomas of pancreatic, biliary, ampullary and duodenal origin. Bronsert P, Kohler I, Werner M, Makowiec F, Kuesters S, Hoeppner J, Hopt UT, Keck T, Bausch D, Wellner UF. BMC Cancer. 2013 Sep 22;13:428. doi: 10.1186/1471-2407-13-428.

 

Co-Autorenschaften 2018

1. Proteome Profiling of Primary Pancreatic Ductal Adenocarcinomas Undergoing Additive Chemoradiation Link ALDH1A1 to Early Local Recurrence and Chemoradiation Resistance. Oria VO, Bronsert P, Thomsen AR, Föll MC, Zamboglou C, Hannibal L, Behringer S, Biniossek ML, Schreiber C, Grosu AL, Bolm L, Rades D, Keck T, Werner M, Wellner UF, Schilling O. Transl Oncol. 2018 Aug 29;11(6):1307-1322. doi: 10.1016/j.tranon.2018.08.001.

2. ATP in the tumour microenvironment drives expression of nfP2X7, a key mediator of cancer cell survival. Gilbert SM, Oliphant CJ, Hassan S, Peille AL, Bronsert P, Falzoni S, Di Virgilio F, McNulty S, Lara R. Oncogene. 2018 Aug 7. doi: 10.1038/s41388-018-0426-6.

3. Does the site of primary colorectal cancer influence the outcome after resection of isolated liver metastases? Makowiec F, Menzel M, Bronsert P, Holzner PA, Klock A, Lang SA, Fichtner-Feigl S, Neeff HP. Dig Liver Dis. 2018 Jun 30. pii: S1590-8658(18)30806-5. doi: 10.1016/j.dld.2018.06.019.

4. Intraoperative detection of circulating tumor cells in pulmonary venous blood during metastasectomy for colorectal lung metastases. Le UT, Bronsert P, Picardo F, Riethdorf S, Haager B, Rylski B, Czerny M, Beyersdorf F, Wiesemann S, Pantel K, Passlick B, Kaifi JT, Schmid S. Sci Rep. 2018 Jun 8;8(1):8751. doi: 10.1038/s41598-018-26410-8.

5. Focal dose escalation for prostate cancer using 68Ga-HBED-CC PSMA PET/CT and MRI: a planning study based on histology reference. Zamboglou C, Thomann B, Koubar K, Bronsert P, Krauss T, Rischke HC, Sachpazidis I, Drendel V, Salman N, Reichel K, Jilg CA, Werner M, Meyer PT, Bock M, Baltas D, Grosu AL. Radiat Oncol. 2018 May 2;13(1):81. doi: 10.1186/s13014-018-1036-8.

6. Identification and Validation of a Diagnostic and Prognostic Multi-Gene Biomarker Panel for Pancreatic Ductal Adenocarcinoma. Klett H, Fuellgraf H, Levit-Zerdoun E, Hussung S, Kowar S, Küsters S, Bronsert P, Werner M, Wittel U, Fritsch R, Busch H, Boerries M. Front Genet. 2018 Apr 5;9:108. doi: 10.3389/fgene.2018.00108. eCollection 2018.

7. Reproducible proteomics sample preparation for single FFPE tissue slices using acid-labile surfactant and direct trypsinization. Foell MC, Fahrner M, Oria VO, Kühs M, Biniossek ML, Werner M, Bronsert P, Schilling O. Clinical Proteomics, Accepted 2018

8. Intrahepatic cholangiocarcinoma : Results after 84 resections. Neeff HP, Holzner PA, Menzel M, Bronsert P, Klock A, Lang SA, Fichtner-Feigl S, Hopt UT, Makowiec F. Chirurg. 2018 Feb 20. doi: 10.1007/s00104-018-0609-2.

9. Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study. van der Putten LJM, Visser NCM, van de Vijver K, Santacana M, Bronsert P, Bulten J, Hirschfeld M, Colas E, Gil-Moreno A, Garcia A, Mancebo G, Alameda F, Trovik J, Kopperud RK, Huvila J, Schrauwen S, Koskas M, Walker F, Weinberger V, Minar L, Jandakova E, Snijders MPLM, van den Berg-van Erp S, Matias-Guiu X, Salvesen HB, Werner HMJ, Amant F, Massuger LFAG, Pijnenborg JMA. Int J Gynecol Cancer. 2018 Jan 10. doi: 10.1097/IGC.0000000000001187.

10. Viability and biocompatibility of an adhesive system for intrarenal embedding and endoscopic removal of small residual fragments in minimally-invasive stone treatment in an in vivo pig model. Hein S, Schoeb DS, Grunwald I, Richter K, Haberstroh J, Seidl M, Bronsert P, Wetterauer U, Schoenthaler M, Miernik A. World J Urol. 2018 Jan 24. doi: 10.1007/s00345-018-2188-8.

11. Prognostic influence of hepatic margin after resection of colorectal liver metastasis: role of modern preoperative chemotherapy. Makowiec F, Bronsert P, Klock A, Hopt UT, Neeff HP. Int J Colorectal Dis. 2018 Jan;33(1):71-78. doi: 10.1007/s00384-017-2916-3.

 

2017

12. A deep conical agarose microwell array for adhesion independent three-dimensional cell culture and dynamic volume measurement. Thomsen AR, Aldrian C, Bronsert P, Thomann Y, Nanko N, Melin N, Rücker G, Follo M, Grosu AL, Niedermann G, Layer PG, Heselich A, Lund PG. Lab Chip. 2017 Dec 19;18(1):179-189. doi: 10.1039/c7lc00832e.

13. A molecular intravascular ultrasound contrast agent allows detection of activated platelets on the surface of symptomatic human plaques. Maier A, Plaza-Heck P, Meixner F, Guenther F, Kaufmann BA, Kramer M, Heidt T, Zirlik A, Hilgendorf I, Reinöhl J, Stachon P, Bronsert P, Birkemeyer R, Neudorfer I, Peter K, Bode C, von Zur Mühlen C. Atherosclerosis. 2017 Dec;267:68-77. doi: 10.1016/j.atherosclerosis.2017.10.029. Epub 2017 Oct 24.

14. KDM4 Inhibition Targets Breast Cancer Stem-like Cells. Metzger E, Stepputtis SS, Strietz J, Preca BT, Urban S, Willmann D, Allen A, Zenk F, Iovino N, Bronsert P, Proske A, Follo M, Boerries M, Stickeler E, Xu J, Wallace MB, Stafford JA, Kanouni T, Maurer J, Schüle R. Cancer Res. 2017 Nov 1;77(21):5900-5912. doi: 10.1158/0008-5472.CAN-17-1754. Epub 2017 Sep 7.

15. Anti-Phosphohistone H3-Positive Mitoses Are Linked to Pathological Response in Neoadjuvantly Treated Breast Cancer. Sillem M, Timme S, Bronsert P, Bogatyreva L, Hauschke D, Zur Hausen A, Werner M, Stickeler E. Breast Care (Basel). 2017 Sep;12(4):244-250. doi: 10.1159/000463377. Epub 2017 Aug 2. Erratum in: Breast Care (Basel). 2017 Oct;12 (5):343.

16. Survival outcome and prognostic factors after pancreatoduodenectomy for distal bile duct carcinoma: a retrospective multicenter study. Petrova E, Rückert F, Zach S, Shen Y, Weitz J, Grützmann R, Wittel UA, Makowiec F, Hopt UT, Bronsert P, Kühn F, Rau BM, Izrailov RE, Khatkov IE, Lapshyn H, Bolm L, Bausch D, Keck T, Wellner UF, Seifert G. Langenbecks Arch Surg. 2017 Aug;402(5):831-840. doi: 10.1007/s00423-017-1590-9. Epub 2017 Jun 13.

17. Pancreatic cancer: Circulating Tumor Cells and Primary Tumors show Heterogeneous KRAS Mutations. Kulemann B, Rösch S, Seifert S, Timme S, Bronsert P, Seifert G, Martini V, Kuvendjiska J, Glatz T, Hussung S, Fritsch R, Becker H, Pitman MB, Hoeppner J. Sci Rep. 2017 Jul 3;7(1):4510. doi: 10.1038/s41598-017-04601-z.

18. The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. Krebs AM, Mitschke J, Losada ML, Schmalhofer O, Boerries M, Busch H, Boettcher M, Mougiakakos D, Reichardt W, Bronsert P, Brunton VG, Pilarsky C, Winkler TH, Brabletz S, Stemmler MP, Brabletz T. Nat Cell Biol. 2017 Apr 17. doi: 10.1038/ncb3513.

19. Sensitivity of Helicobacter pylori detection by Giemsa staining is poor in comparison with immunohistochemistry and fluorescent in situ hybridization and strongly depends on inflammatory activity. Kocsmár É, Szirtes I, Kramer Z, Szijártó A, Bene L, Buzás GM, Kenessey I, Bronsert P, Csanadi A, Lutz L, Werner M, Wellner UF, Kiss A, Schaff Z, Lotz G. Helicobacter. 2017 Apr 12. doi: 10.1111/hel.12387.

20. A novel ZEB1/HAS2 positive feedback loop promotes EMT in breast cancer. Preca BT, Bajdak K, Mock K, Lehmann W, Sundararajan V, Bronsert P, Matzge-Ogi A, Orian-Rousseau V, Brabletz S, Brabletz T, Maurer J, Stemmler MP. Oncotarget. 2017 Feb 14;8(7):11530-11543. doi: 10.18632/oncotarget.14563.

 

2016

21. Pregnancy Specific β-1 Glycoprotein 1 is Expressed in Pancreatic Ductal Adenocarcinoma and its Subcellular Localization Correlates with Overall Survival. Shahinian JH, Fuellgraf H, Tholen S, Mastroianni J, Knopf JD, Kuehs M, Mayer B, Schlimpert M, Kulemann B, Kuesters S, Hoeppner J, Wellner UF, Werner M, Hopt UT, Zeiser R, Bronsert P, Schilling O. J Cancer. 2016 Oct 17;7(14):2018-2027. eCollection 2016.

22. TNM-O: ontology support for staging of malignant tumours. Boeker M, França F, Bronsert P, Schulz S. J Biomed Semantics. 2016 Nov 14;7(1):64.

23. ERN1 and ALPK1 inhibit differentiation of bi-potential tumor-initiating cells in human breast cancer. Strietz J, Stepputtis SS, Preca BT, Vannier C, Kim MM, Castro DJ, Au Q, Boerries M, Busch H, Aza-Blanc P, Heynen-Genel S, Bronsert P, Kuster B, Stickeler E, Brabletz T, Oshima RG, Maurer J. Oncotarget. 2016 Dec 13;7(50):83278-83293. doi: 10.18632/oncotarget.13086.

24. L1CAM expression in endometrial carcinomas: an ENITEC collaboration study. van der Putten LJ, Visser NC, van de Vijver K, Santacana M, Bronsert P, Bulten J, Hirschfeld M, Colas E, Gil-Moreno A, Garcia A, Mancebo G, Alameda F, Trovik J, Kopperud RK, Huvila J, Schrauwen S, Koskas M, Walker F, Weinberger V, Minar L, Jandakova E, Snijders MP, van den Berg-van Erp S, Matias-Guiu X, Salvesen HB, Amant F, Massuger LF, Pijnenborg JM. Br J Cancer. 2016 Sep 6;115(6):716-24. doi: 10.1038/bjc.2016.235. Epub 2016 Aug 9.

25. ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286). Hoeppner J, Lordick F, Brunner T, Glatz T, Bronsert P, Röthling N, Schmoor C, Lorenz D, Ell C, Hopt UT, Siewert JR. BMC Cancer. 2016 Jul 19;16:503. doi: 10.1186/s12885-016-2564-y.

26. Gastrin-releasing Peptide Receptor Imaging in Breast Cancer Using the Receptor Antagonist 68Ga-RM2 And PET Stoykow C, Erbes T, Maecke HR, Bulla S, Bartholomä M, Mayer S, Drendel V, Bronsert P, Werner M, Gitsch G, Weber WA, Stickeler E, Meyer PT. Theranostics 2016; 6(10):1641-1650. doi:10.7150/thno.14958.

27. Formalin-Fixed, Paraffin-Embedded Tissues (FFPE) as a Robust Source for the Profiling of Native and Protease-Generated Protein Amino Termini. Lai ZW, Weisser J, Nilse L, Costa F, Keller E, Tholen M, Kizhakkedathu JN, Biniossek M, Bronsert P, Schilling O. Mol Cell Proteomics. 2016 Jun;15(6):2203-13. doi: 10.1074/mcp.O115.056515. Epub 2016 Apr 17.

28. Structured reporting ensures complete content and quick detection of essential data in pathology reports of oncological breast resection specimens. Aumann K, Niermann K, Asberger J, Wellner U, Bronsert P, Erbes T, Hauschke D, Stickeler E, Gitsch G, Kayser G, Werner M. Breast Cancer Res Treat. 2016 Apr;156(3):495-500. doi: 10.1007/s10549-016-3769-0. Epub 2016 Apr 8.

 

2015

29. KRAS mutations in pancreatic circulating tumor cells: a pilot study. Kulemann B, Liss AS, Warshaw AL, Seifert S, Bronsert P, Glatz T, Pitman MB, Hoeppner J. Tumour Biol. 2015 Dec 18.

30. Alternative splicing of synuclein gamma in endometrial cancer: identification of a novel isoform. Schaal K, Hirschfeld M, Bronsert P, Füllgraf H, Jäger M, Herde B, Nöthling C, Mayer S, Erbes T, Stickeler E. Oncotarget. 2015 Sep 8;6(26):22553-63.

31. Identification of a blood-borne miRNA signature of synovial sarcoma. Fricke A, Ullrich PV, Heinz J, Pfeifer D, Scholber J, Herget GW, Hauschild O, Bronsert P, Stark GB, Bannasch H, Eisenhardt SU, Braig D. Mol Cancer. 2015 Aug 7;14:151. doi: 10.1186/s12943-015-0424-z.

32. Quantitative proteomic analysis of formalin-fixed, paraffin-embedded clear cell renal cell carcinoma tissue using stable isotopic dimethylation of primary amines. Weißer J, Lai ZW, Bronsert P, Kuehs M, Drendel V, Timme S, Kuesters S, Jilg CA, Wellner UF, Lassmann S, Werner M, Biniossek ML, Schilling O. BMC Genomics. 2015 Jul 29;16:559. doi: 10.1186/s12864-015-1768-x.

33. Perioperative platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: Postoperative chemotherapy has a substantial impact on outcome. Glatz T, Bronsert P, Schäfer M, Kulemann B, Marjanovic G, Sick O, Hopt UT, Zirlik K, Makowiec F, Hoeppner J. Eur J Surg Oncol. 2015 Jul 29. pii: S0748-7983(15)00553-3. doi: 10.1016/j.ejso.2015.07.010.

34. Pancreatogastrostomy Versus Pancreatojejunostomy for RECOnstruction After PANCreatoduodenectomy (RECOPANC, DRKS 00000767): Perioperative and Long-term Results of a Multicenter Randomized Controlled Trial. Keck T, Wellner UF, Bahra M, Klein F, Sick O, Niedergethmann M, Wilhelm TJ, Farkas SA, Börner T, Bruns C, Kleespies A, Kleeff J, Mihaljevic AL, Uhl W, Chromik A, Fendrich V, Heeger K, Padberg W, Hecker A, Neumann UP, Junge K, Kalff JC, Glowka TR, Werner J, Knebel P, Piso P, Mayr M, Izbicki J, Vashist Y, Bronsert P, Bruckner T, Limprecht R, Diener MK, Rossion I, Wegener I, Hopt UT. Ann Surg. 2015 Jul 1.

35. Stress-resistant Translation of Cathepsin L mRNA in Breast Cancer Progression. Stress-resistant Translation of Cathepsin L mRNA in Breast Cancer Progression. Tholen M, Wolanski J, Stolze B, Chiabudini M, Gajda M, Bronsert P, Stickeler E, Rospert S, Reinheckel T. J Biol Chem. 2015 Jun 19;290(25):15758-69. doi: 10.1074/jbc.M114.624353. Epub 2015 May

36. Assessing quality and functionality of DNA isolated from FFPE tissues through external quality assessment in tissue banks. Ahmad-Nejad P, Duda A, Sucker A, Werner M, Bronsert P, Stickeler E, Reifenberger G, Malzkorn B, Oberländer M, Habermann JK, Bruch HP, Linnebacher M, Schadendorf D, Neumaier M. Clin Chem Lab Med. 2015 Jun 6. pii: /j/cclm.ahead-of-print/cclm-2014-1202/cclm-2014-1202.xml. doi: 10.1515/cclm-2014-1202

37. ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat. Meidhof S, Brabletz S, Lehmann W, Preca BT, Mock K, Ruh M, Schüler J, Berthold M, Weber A, Burk U, Lübbert M, Puhr M, Culig Z, Wellner U, Keck T, Bronsert P, Küsters S, Hopt UT, Stemmler MP, Brabletz T. EMBO Mol Med. 2015 Apr 14;7(6):831-47. doi: 10.15252/emmm.201404396.

38. Role of cannabinoid receptor CB2 in HER2 pro-oncogenic signaling in breast cancer. Pérez-Gómez E, Andradas C, Blasco-Benito S, Caffarel MM, García-Taboada E, Villa-Morales M, Moreno E, Hamann S, Martín-Villar E, Flores JM, Wenners A, Alkatout I, Klapper W, Röcken C, Bronsert P, Stickeler E, Staebler A, Bauer M, Arnold N, Soriano J, Pérez-Martínez M, Megías D, Moreno-Bueno G, Ortega-Gutiérrez S, Artola M, Vázquez-Villa H, Quintanilla M, Fernández-Piqueras J, Canela EI, McCormick PJ, Guzmán M, Sánchez C. J Natl Cancer Inst. 2015 Apr 8;107(6):djv077. doi: 10.1093/jnci/djv077. Print 2015 Jun.

39. Detailed analysis of epithelial-mesenchymal transition and tumor budding identifies predictors of long-term survival in pancreatic ductal adenocarcinoma. Kohler I, Bronsert P, Timme S, Werner M, Brabletz T, Hopt UT, Schilling O, Bausch D, Keck T, Wellner UF. J Gastroenterol Hepatol. 2015 Mar;30 Suppl 1:78-84. doi: 10.1111/jgh.12752.

40. Perioperative and long-term outcome after standard pancreaticoduodenectomy, additional portal vein and multivisceral resection for pancreatic head cancer. Perioperative and long-term outcome after standard pancreaticoduodenectomy, additional portal vein and multivisceral resection for pancreatic head cancer.Kulemann B, Hoeppner J, Wittel U, Glatz T, Keck T, Wellner UF, Bronsert P, Sick O, Hopt UT, Makowiec F, Riediger H. J Gastrointest Surg. 2015 Mar;19(3):438-44. doi: 10.1007/s11605-014-2725-8. Epub 2015 Jan 8.

41. Radiotherapy for SMAD4-negative musculoskeletal lesions from pancreatic cancer: case report and review. Zamboglou C, Bronsert P, Küsters S, Salm N, Azèmar M, Brunner T. Strahlenther Onkol. 2015 Jan;191(1):67-72. doi: 10.1007/s00066-014-0764-4. Epub 2014 Oct 10

 

2014

42. Histological Analysis of γδ T Lymphocytes Infiltrating Human Triple-Negative Breast Carcinomas. Hidalgo JV, Bronsert P, Orlowska-Volk M, Díaz LB, Stickeler E, Werner M, Schmitt-Graeff A, Kayser G, Malkovsky M, Fisch P. Front Immunol. 2014 Dec 10;5:632. doi: 10.3389/fimmu.2014.00632. eCollection 2014. Hybrid laparoscopic versus open pylorus-preserving pancreatoduodenectomy: retrospective matched case comparison in 80 patients.

43. Wellner UF, Küsters S, Sick O, Busch C, Bausch D, Bronsert P, Hopt UT, Karcz KW, Keck T. Langenbecks Arch Surg. 2014 Oct;399(7):849-56. doi: 10.1007/s00423-014-1236-0. Dual-contrast molecular imaging allows noninvasive characterization of myocardial ischemia/reperfusion injury after coronary vessel occlusion in mice by magnetic resonance imaging.

44. von Elverfeldt D, Maier A, Duerschmied D, Braig M, Witsch T, Wang X, Mauler M, Neudorfer I, Menza M, Idzko M, Zirlik A, Heidt T, Bronsert P, Bode C, Peter K, von Zur Muhlen C. Circulation. 2014 Aug 19;130(8):676-87. doi: 10.1161/CIRCULATIONAHA.113.008157.

45. Double 90 Degrees Counterrotated End-to-End-Anastomosis: An Experimental Study of an Intestinal Anastomosis Technique. Holzner P, Kulemann B, Seifert G, Glatz T, Chikhladze S, Höppner J, Hopt U, Timme S, Bronsert P, Sick O, Zhou C, Marjanovic G. Eur J Pediatr Surg. 2014 May 12.

46. Multimodal treatment of locally advanced esophageal adenocarcinoma: which regimen should we choose? Outcome analysis of perioperative chemotherapy versus neoadjuvant chemoradiation in 105 patients. Hoeppner J, Zirlik K, Brunner T, Bronsert P, Kulemann B, Sick O, Marjanovic G, Hopt UT, Makowiec F. J Surg Oncol. 2014 Mar;109(3):287-93. doi: 10.1002/jso.23498.

 

2013

47. Intraoperative crystalloid overload leads to substantial inflammatory infiltration of intestinal anastomoses-a histomorphological analysis. Kulemann B, Timme S, Seifert G, Holzner PA, Glatz T, Sick O, Chikhladze S, Bronsert P, Hoeppner J, Werner M, Hopt UT, Marjanovic G. Surgery. 2013 Sep;154(3):596-603. doi: 10.1016/j.surg.2013.04.010.

48. The format type has impact on the quality of pathology reports of oncological lung resection specimens. Aumann K, Kayser G, Amann D, Bronsert P, Hauschke D, Palade E, Passlick B, Werner M. Lung Cancer. 2013 Sep;81(3):382-7. doi: 10.1016/j.lungcan.2013.05.017.

49. Improved long-term survival after esophagectomy for esophageal cancer: influence of epidemiologic shift and neoadjuvant therapy. Makowiec F, Baier P, Kulemann B, Marjanovic G, Bronsert P, Zirlik K, Henke M, Hopt UT, Hoeppner J. J Gastrointest Surg. 2013 Jul;17(7):1193-201. doi: 10.1007/s11605-013-2212-7.

50. Limited resection for duodenal gastrointestinal stromal tumors: Surgical management and clinical outcome. Hoeppner J, Kulemann B, Marjanovic G, Bronsert P, Hopt UT. World J Gastrointest Surg. 2013 Feb 27;5(2):16-21.

51. Outcome after repeat resection of liver metastases from colorectal cancer. Neeff HP, Drognitz O, Holzner P, Klock A, Bronsert P, Hopt UT, Makowiec F. Int J Colorectal Dis. 2013 Aug;28(8):1135-41. doi: 10.1007/s00384-013-1670-4.

Kontakt Forschung

Generelle Anfragen zur Forschung am Institut
pathologie.projektkoord@uniklinik-freiburg.de

Anprechpartner in den AGs
auf den jeweiligen Seiten

Forschungsverbünde:
BMBF
CCCF
CCI
DKTK
SFB 850
SFB 992

Institut für Klinische Pathologie
Universitätsklinikum Freiburg
Breisacher Str. 115a
79106 Freiburg
Tel.: +49 761 270 80060 (Sekretariat)
Fax: +49 761 270-80040
pathologie.direktion
@uniklinik-freiburg.de


Postanschrift:

Postfach 214
79002 Freiburg